首页 | 本学科首页   官方微博 | 高级检索  
     


Defining Staged Procedures for Percutaneous Coronary Intervention Trials: A Guidance Document
Authors:Ernest Spitzer  Eugène McFadden  Pascal Vranckx  Ton de Vries  Ben Ren  Carlos Collet  Yoshinobu Onuma  Hector M. Garcia-Garcia  Renato D. Lopes  Gregg W. Stone  Donald E. Cutlip  Patrick W. Serruys
Affiliation:1. Cardialysis Core Laboratories and Clinical Trial Management, Rotterdam, the Netherlands;2. Department of Cardiology, Thoraxcenter, Erasmus University Medical Center, Rotterdam, the Netherlands;3. Department of Cardiology, Cork University Hospital, Cork, Ireland;4. Department of Cardiology and Critical Care Medicine, Hartcentrum Hasselt, Jessa Ziekenhuis, Faculty of Medicine and Life Sciences Hasselt University, Hasselt, Belgium;5. Department of Cardiology, Academic Medical Center, Amsterdam, the Netherlands;6. Department of Cardiology, MedStar Washington Hospital Center, Washington, DC;7. Division of Cardiology, Duke University Medical Center/Duke Clinical Research Institute, Durham, North Carolina;8. Clinical Trials Center, Cardiovascular Research Foundation and Division of Cardiology, Columbia University Medical Center, New York, New York;9. Baim Institute for Clinical Research, Boston, Massachusetts;10. Beth Israel Deaconess Medical Center, Boston, Massachusetts;11. International Centre for Circulatory Health, NHLI, Imperial College London, London, United Kingdom
Abstract:Patients in coronary intervention trials may require more than 1 procedure to complete the intended revascularization strategy. However, these staged interventions are not consistently defined. Standardized definitions are needed to allow meaningful comparisons of this outcome among trials. This document provides guidance on relevant parameters involving staged procedures, including minimum data collection and consistent classification of coronary procedures initially identified as staged; the aim is to achieve consistency among clinical trialists, sponsors, health authorities, and regulators. Definitions were developed jointly among representatives of academic institutions and clinical research organizations based on clinical trial experience and published literature. Reasons for staged procedures were identified and include baseline kidney function, contrast load and radiation exposure, lesion complexity, and patient or operator fatigue. Moreover, nonclinical reasons include procedure scheduling and reimbursement. Management of staged procedures should be a standalone section in clinical trial protocols and clinical events committee charters. These documents should clearly define a time window for staged procedures that allows latitude for local policies, while respecting accepted clinical guidelines, and consistency with study objectives. Investigators should document in the case report form the intent to stage a procedure, the lesions to be treated, and the reasons for staging, preferably before randomization. Ideally, all reinterventions, or at least all procedures performed after the recommended time window, those in which data suggest an anticipated procedure due to a worsening condition and those where a revascularization is attempted in the target vessel, should be reviewed by an independent clinical events committee.
Keywords:clinical endpoint adjudication  clinical trial  coronary revascularization  staged procedure  ARC  Academic Research Consortium  CEC  clinical events committee  CTO  chronic total occlusion  LAD  left anterior descending coronary artery  PCI  percutaneous coronary intervention  STEMI  ST-segment elevation myocardial infarction
本文献已被 ScienceDirect 等数据库收录!
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号